Chemical Proteomics-Guided Discovery of Covalent Ligands for Cancer Proteins [0.03%]
基于化学蛋白质组学的抗癌药物导向发现及其机制研究
Xiaoyu Zhang,Benjamin F Cravatt
Xiaoyu Zhang
Advances in genome sequencing and editing technologies have enriched our understanding of the biochemical pathways that drive tumorigenesis. Translating this knowledge into new medicines for cancer treatment, however, remains challenging, a...
Jordan H Driskill,Josephine K Dermawan,Cristina R Antonescu et al.
Jordan H Driskill et al.
Gene fusions are well-known drivers of cancer and are potent targets for molecular therapy. An emerging spectrum of human tumors harbors recurrent and pathognomonic gene fusions that involve the transcriptional coactivator YAP1 (which encod...
Colleen R Reczek,Navdeep S Chandel
Colleen R Reczek
Reactive oxygen species (ROS), now appreciated for their cellular signaling capabilities, have a dual role in cancer. On the one hand, ROS can promote protumorigenic signaling, facilitating cancer cell proliferation, survival, and adaptatio...
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy [0.03%]
PTPN11/SHP2在 carcinogenesis中的复杂作用及靶向SHP2在癌症治疗中的前景
Alexander Scheiter,Li-Chun Lu,Lilian H Gao et al.
Alexander Scheiter et al.
The non-receptor tyrosine phosphatase SHP2 has been at the center of cell signaling research for three decades. SHP2 is required to fully activate the RTK-RAS-ERK cascade, although the underlying mechanisms are not completely understood. PT...
Charles L Limoli,Marie-Catherine Vozenin
Charles L Limoli
Ultrahigh-dose rate FLASH radiotherapy (FLASH-RT) is a potentially paradigm-shifting treatment modality that holds the promise of expanding the therapeutic index for nearly any cancer. At the heart of this exciting technology comes the capa...
Erin W Meermeier,P Leif Bergsagel,Marta Chesi
Erin W Meermeier
Recent therapeutic advances have significantly improved the outcome for patients with multiple myeloma (MM). The backbone of successful standard therapy is the combination of Ikaros degraders, glucocorticoids, and proteasome inhibitors that...
Yonina R Murciano-Goroff,Manik Uppal,Monica Chen et al.
Yonina R Murciano-Goroff et al.
Large-scale tumor molecular profiling has revealed that diverse cancer histologies are driven by common pathways with unifying biomarkers that can be exploited therapeutically. Disease-agnostic basket trials have been increasingly utilized ...
Daniel A Bonsor,Dhirendra K Simanshu
Daniel A Bonsor
Mutations in RAS proteins play a pivotal role in the development of human cancers, driving persistent RAF activation and deregulating the Mitogen-Activated Protein Kinase (MAPK) signaling pathway. While progress has been made in targeting s...
Joelle P Straehla,David A Reardon,Patrick Y Wen et al.
Joelle P Straehla et al.
The blood-brain barrier is critically important for the treatment of both primary and metastatic cancers of the central nervous system (CNS). Clinical outcomes for patients with primary CNS tumors are poor and have not significantly improve...
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy [0.03%]
基于T细胞受体的细胞治疗靶向驱动癌基因及其他公共新抗原
Tijana Martinov,Philip D Greenberg
Tijana Martinov
T cell reactivity to tumor-specific neoantigens can drive endogenous and therapeutically induced antitumor immunity. However, most tumor-specific neoantigens are unique to each patient (private) and targeting them requires personalized ther...